The Phase 3 trial investigating fenebrutinib for relapsing multiple sclerosis (RMS) reached its primary completion on January 27, 2026. This milestone signifies the completion of data collection for the primary endpoint analysis in the study, which compares fenebrutinib to teriflunomide.
Background
The study addresses Relapsing Multiple Sclerosis (RMS), a chronic autoimmune disease affecting the central nervous system for which new therapeutic options are continually being evaluated.
Trial design
The study, identified as NCT04586010, is a Phase 3 trial titled "A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)." It has an enrollment of 746 participants. The trial investigates fenebrutinib in individuals diagnosed with Relapsing Multiple Sclerosis. Participants are randomized 1:1 to receive either fenebrutinib or teriflunomide. The study's primary objective is to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate.
What this means
The primary completion of the Phase 3 trial for fenebrutinib in Relapsing Multiple Sclerosis marks a significant step towards the potential availability of new data for this investigational treatment. Clinicians and researchers will await the disclosure of the trial's results to understand the efficacy and safety profile of fenebrutinib compared to teriflunomide in this patient population.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT04586010, titled "A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)," was recorded on January 27, 2026, on clinicaltrials.gov.